ArticleTranslational cancer research2025
Diagnostic accuracy of SHOX-2 methylation for malignant pleural effusion: a systematic review and meta-analysis.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Some studies have assessed the diagnostic value of SHOX-2 methylation for malignant pleural effusion (MPE), but their findings were inconsistent. This study aimed to conduct a systematic review and meta-analysis to evaluate the diagnostic accuracy of SHOX-2 methylation for MPE. Methods: We searched the PubMed and Web of Science databases to identify studies involving SHOX-2 methylation in diagnosing MPE. The last search date was in December 2024. We evaluated the quality of the included studies using the revised Quality Assessment of Diagnostic Accuracy Studies tool-2 (QUADAS-2). A bivariate model was used to pool the sensitivity, specificity, and their 95% confidence intervals (CIs) of SHOX-2 methylation. The overall diagnostic accuracy of SHOX-2 methylation was assessed by a summary receiver operating characteristic (sROC) curve. The publication bias was analyzed using Deek's test. Results: Six studies with 613 MPE patients and 723 benign pleural effusion (BPE) patients were included. The pooled sensitivity (95% CI) and specificity (95% CI) of SHOX-2 methylation were 0.64 (0.36-0.85) and 0.96 (0.92-0.98), respectively. The area under the sROC curve was 0.96 (95% CI: 0.94-0.97). There was no publication bias across the eligible studies. Conclusions: SHOX-2 methylation has a moderate diagnostic value for MPE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.